Allspring Global Investments’s iBio IBIO Stock Holding History

Allspring Global Investments’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-169	Closed	-$36K	–	2798
2022 Q1	$36K	Buy	+169	New	+$35.4K	﹤0.01%	2883

Other funds holding IBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allspring Global Investments's IBIO Position: Q2 2022 in Review

Allspring Global Investments sold out of iBio (IBIO) in Q2 2022, closing a stake of 169 shares — an estimated $36K sold.

Allspring Global Investments first reported a position in IBIO in Q1 2022 and held it in 1 quarter. The position peaked at $36K in Q1 2022. 53 funds tracked by Wall St. Rank hold IBIO as of Q2 2022.

Allspring Global Investments reported no remaining iBio position as of Q2 2022 after selling out during the quarter.
Allspring Global Investments sold 169 iBio shares in Q2 2022, an estimated $36K.
Allspring Global Investments first reported a position in iBio in Q1 2022 and held it in 1 quarter.
Allspring Global Investments's iBio position peaked at $36K in Q1 2022.
53 funds tracked by Wall St. Rank held iBio as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.